粒细胞集落刺激因子对靶细胞的作用机制及其常用制剂的临床药理研究和应用进展(6)
[27] BLAIR HA，SCOTT LJ. Tbo-filgrastim：a review in neutropenic conditions[J]. Bio Drugs，2016，30(2)：153-160.
[28] MATSUGUMA K，MATSUKI S，EUNHEE C，et al. Pharmacokinetics and pharmacodynamics of FSK0808 and Gran after single intravenous drip administration or single subcutaneous administration：comparative study in healthy Japanese adult male subjects[J]. Drug Dev Ind Pharm，2015，41(3)：470-475.
[29] CROBU D，SPINETTI G，SCHREPFER R，et al. Preclinical and clinical phase Ⅰ studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen?[J]. BMC Pharmacol Toxicol，2014.DOI：10.1186/2050-6511- 15-7.
, http://www.100md.com
[30] SVEIKATA A，GUMBREVI?IUS G，SE?TAKAUSKAS K，et al. Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers[J]. Medicina (Kaunas)，2014，50(3)：144-149.
[31] SOURGENS H，LEFR?RE F. A systematic review of available clinical evidence-filgrastim compared with lenograstim[J]. Int J Clin Pharmacol Ther，2011，49(8)：510- 518.
, 百拇医药
[32] MOLINEUX G. Pegylation：engineering improved biopharmaceuticals for oncology[J]. Pharmacotherapy，2003，23(8 Pt 2)：3S-8S.
[33] ZHANG W，JIANG Z，WANG L，et al. An open-label，randomized，multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy[J]. Med Oncol，2015，32(5)：147.
[34] GREEN MD，KOELBL H，BASELGA J，et al. A randomized double-blind multicenter phase Ⅲ study of fixed- dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy[J]. Ann Oncol，2003，14(1)：29-35.
, 百拇医药
[35] SCHOLZ M，ENGEL C，APT D，et al. Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy- G34 and pegfilgrastim in rats[J]. Cell Prolif，2009，42(6)：823-837.
[36] QIN Y，HAN X，WANG L，et al. A phase Ⅰ study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG- CSF) in patients with standard-dose chemotherapy-induced neutropenia[J]. Chin J Cancer Res，2017，29(5)：402-410.
[37] AKPO E，JANSEN IR，MAES E，et al. Cost-utility analysis of lipegfilgrastim compared to pegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in patients with stage Ⅱ-Ⅳ breast cancer[J]. Front Pharmacol，2017.DOI：10.3389/fphar.2017.00614., 百拇医药(李菲 王斌 舒斯云 马林)
[28] MATSUGUMA K，MATSUKI S，EUNHEE C，et al. Pharmacokinetics and pharmacodynamics of FSK0808 and Gran after single intravenous drip administration or single subcutaneous administration：comparative study in healthy Japanese adult male subjects[J]. Drug Dev Ind Pharm，2015，41(3)：470-475.
[29] CROBU D，SPINETTI G，SCHREPFER R，et al. Preclinical and clinical phase Ⅰ studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen?[J]. BMC Pharmacol Toxicol，2014.DOI：10.1186/2050-6511- 15-7.
, http://www.100md.com
[30] SVEIKATA A，GUMBREVI?IUS G，SE?TAKAUSKAS K，et al. Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers[J]. Medicina (Kaunas)，2014，50(3)：144-149.
[31] SOURGENS H，LEFR?RE F. A systematic review of available clinical evidence-filgrastim compared with lenograstim[J]. Int J Clin Pharmacol Ther，2011，49(8)：510- 518.
, 百拇医药
[32] MOLINEUX G. Pegylation：engineering improved biopharmaceuticals for oncology[J]. Pharmacotherapy，2003，23(8 Pt 2)：3S-8S.
[33] ZHANG W，JIANG Z，WANG L，et al. An open-label，randomized，multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy[J]. Med Oncol，2015，32(5)：147.
[34] GREEN MD，KOELBL H，BASELGA J，et al. A randomized double-blind multicenter phase Ⅲ study of fixed- dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy[J]. Ann Oncol，2003，14(1)：29-35.
, 百拇医药
[35] SCHOLZ M，ENGEL C，APT D，et al. Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy- G34 and pegfilgrastim in rats[J]. Cell Prolif，2009，42(6)：823-837.
[36] QIN Y，HAN X，WANG L，et al. A phase Ⅰ study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG- CSF) in patients with standard-dose chemotherapy-induced neutropenia[J]. Chin J Cancer Res，2017，29(5)：402-410.
[37] AKPO E，JANSEN IR，MAES E，et al. Cost-utility analysis of lipegfilgrastim compared to pegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in patients with stage Ⅱ-Ⅳ breast cancer[J]. Front Pharmacol，2017.DOI：10.3389/fphar.2017.00614., 百拇医药(李菲 王斌 舒斯云 马林)